NEWSTIER

Fri, Aug 28
Status: JUNE AliveWelcome: Visitordata 27s old

Latest Headlines

163 categorized of 405
BENZINGA10:352m agobearish

BTIG Reiterates Buy on IREN, Maintains $80 Price Target

BTIG Reiterates Buy on IREN, Maintains $80 Price Target | 6:35 AM EDT, August 28, 2026 (Benzinga Newswire) BTIG analyst Gregory Lewis reiterates IREN (NASDAQ:IREN) with a Buy and maintains $80 price target. Write to Benzinga at editorial@benzinga.com
ANALYST ACTIONS / TARGET/MAINTAIN
GLOBE_NEWS_WIRE10:353m agobullish

MoneyHero Group to Announce Second Quarter 2026 Results

MoneyHero Group to Announce Second Quarter 2026 Results | HONG KONG and SINGAPORE, Aug. 28, 2026 (GLOBE NEWSWIRE) -- MoneyHero Limited (Nasdaq: MNY) (“MoneyHero” or the “Company”), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage…
BENZINGA10:344m ago

BTIG Reiterates Buy on HealthEquity, Maintains $115 Price Target

BTIG Reiterates Buy on HealthEquity, Maintains $115 Price Target | 6:34 AM EDT, August 28, 2026 (Benzinga Newswire) BTIG analyst David Larsen reiterates HealthEquity (NASDAQ:HQY) with a Buy and maintains $115 price target. Write to Benzinga at editorial@benzinga.com
ANALYST ACTIONS / TARGET/MAINTAIN
MIDNIGHT_TRADER10:316m ago

Truist Raises Price Target on Dollar General to $138 From $114, Keeps Hold Rating

Truist Raises Price Target on Dollar General to $138 From $114, Keeps Hold Rating | 06:31 AM EDT, 08/28/2026 (MT Newswires) -- Dollar General (DG) has an average rating of hold and mean price target of $138.74, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and econ…
ANALYST ACTIONS / TARGET/MAINTAINANALYST ACTIONS / UPGRADE
MIDNIGHT_TRADER10:307m agobullish

--Cytokinetics Phase 3 Trial Shows Aficamten Improves Heart Disease Symptoms

--Cytokinetics Phase 3 Trial Shows Aficamten Improves Heart Disease Symptoms | 06:30 AM EDT, 08/28/2026 (MT Newswires) -- Cytokinetics (CYTK) said Friday its drug aficamten met both primary endpoints of a Phase 3 clinical trial treating a non-obstructive heart muscle disorder. The medication improv…
REGULATORY & CLINICAL / CLINICAL TRIAL
MIDNIGHT_TRADER10:308m ago

Stifel Adjusts Price Target on Workday to $160 From $115, Keeps Hold Rating

Stifel Adjusts Price Target on Workday to $160 From $115, Keeps Hold Rating | 06:30 AM EDT, 08/28/2026 (MT Newswires) -- Workday (WDAY) has an average rating of overweight and mean price target of $208.69, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic…
ANALYST ACTIONS / TARGET/MAINTAIN
GLOBE_NEWS_WIRE10:308m ago

Range Declares Quarterly Dividend

Range Declares Quarterly Dividend | FORT WORTH, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced that its Board of Directors declared a quarterly cash dividend on its common stock for the third quarter. A dividend of $0.10 per common share is payable…
EARNINGS / RESULTSSHAREHOLDER RETURNS / DIVIDEND
GLOBE_NEWS_WIRE10:308m ago

Avricore Grants Options

Avricore Grants Options | VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) today announces that the Company’s board of directors has approved the granting of stock options (the “Options”) exercisable for a total of 3,300,000 common shares to its direc…
GLOBE_NEWS_WIRE10:308m ago

Prospectiva Resources Commences Drilling at the São Francisco Copper-Gold Project

Prospectiva Resources Commences Drilling at the São Francisco Copper-Gold Project | TORONTO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Prospectiva Resources Ltd. (TSX-V: PSVA) (“Prospectiva” or the “Company”), a Brazil-focused copper and gold exploration company advancing a portfolio of 100%-owned projects…
GLOBE_NEWS_WIRE10:308m ago

G Mining Ventures Announces Normal Course Issuer Bid for Common Shares

G Mining Ventures Announces Normal Course Issuer Bid for Common Shares | BROSSARD, Quebec, Aug. 28, 2026 (GLOBE NEWSWIRE) -- G Mining Ventures Corp. (“GMIN” or the “Corporation”) (TSX: GMIN, OTCQX: GMINF) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted the Corporatio…
MIDNIGHT_TRADER10:298m ago

Citigroup Adjusts Price Target on Workday to $201 From $139, Maintains Neutral Rating

Citigroup Adjusts Price Target on Workday to $201 From $139, Maintains Neutral Rating | 06:29 AM EDT, 08/28/2026 (MT Newswires) -- Workday (WDAY) has an average rating of overweight and mean price target of $207.11, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and…
ANALYST ACTIONS / TARGET/MAINTAIN
MIDNIGHT_TRADER10:299m ago

TD Cowen Adjusts Price Target on Workday to $210 From $220, Keeps Hold Rating

TD Cowen Adjusts Price Target on Workday to $210 From $220, Keeps Hold Rating | 06:29 AM EDT, 08/28/2026 (MT Newswires) -- Workday (WDAY) has an average rating of overweight and mean price target of $208.69, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economi…
ANALYST ACTIONS / TARGET/MAINTAIN